QSI News and Press, Quantum-Si Incorporated From 03/06/23

The Company began shipments of Platinum ™ instruments and expects to book revenue in Q1 2023 The Company projects an extended cash runway into 2026 March 6, 2023-- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the ȁ...

Quantum-Si ( NASDAQ: QSI ) is scheduled to announce Q4 earnings results on Monday, March 6th, before market open. The consensus EPS Estimate is -$0.20 (+4.8% Y/Y) For further details see: Quantum-Si Q4 2022 Earnings Preview

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company TM , today announced that it will be participating in the 43rd Annual Cowen Health Care Conference taking place at the Boston Marriott Cople...

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company TM , today announced that it will report financial results for the fourth quarter and full year 2022 before market open on Monday, March 6, ...

Summary ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. They increased Tesla, Ginkgo Bioworks, and Coinbase Global stakes while decreasing NVIDIA, Fate Therapeutics, and TuSimple Holdings during the quarter. The top three positions are Exact S...

Company Announces Commercial Shipments of Protein Sequencing System, Reveals New Partnerships, and Reaffirms Commitment to Financial Discipline Launched in December 2022, Platinum is the First Commercially Available Next-Generation Single-Molecule Protein Sequencing System Looking to Unlo...

Partnership Joins Protein Sequencing Technology With AI Visualization to Further Unlock the Human Proteome for Novel Drug Discovery Key Takeaways This partnership combines Quantum-Si’s expertise in single molecule protein sequencing with Biovista’s AI visualization t...

Protein Enrichment Kits to Enable Deep Interrogation of Proteoforms through Protein Sequencing Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it ente...

Summary Quantum-Si's technology has potential in drug discovery and biomarker test development. The company's Platinum sequencing platform is set to launch. Platinum sequencing platform expected to drive revenue growth. In a previous article , I exposed that Quantum-Si...

Dec. 22, 2022-- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it will be participating in the 41st Annual J.P. Morgan Healthcare Conference taking place at th...